{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:29:32Z","timestamp":1790314172716,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["219497"],"award-info":[{"award-number":["219497"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30474-8","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:23:54Z","timestamp":1764951834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The unseen impact of affordability: copayment sensitivity for long-acting PrEP among MSM in six European Countries, October 2023\u2013April 2024"],"prefix":"10.1038","volume":"16","author":[{"given":"Haoyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Kolstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne M. L.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai J.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"7","key":"30474_CR1","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2468-2667(21)00112-2","volume":"6","author":"BR Bavinton","year":"2021","unstructured":"Bavinton, B. R. & Grulich, A. E. HIV pre-exposure prophylaxis: scaling up for impact now and in the future. Lancet Public. Health. 6 (7), e528\u2013e33 (2021).","journal-title":"Lancet Public. Health"},{"key":"30474_CR2","unstructured":"Bekker, L-G. et al. Twice-Yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N. Engl. J. Med. ;0(0). (2024)."},{"issue":"7","key":"30474_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl. J. Med. 385 (7), 595\u2013608 (2021).","journal-title":"N Engl. J. Med."},{"key":"30474_CR4","unstructured":"ViiV Healthcare. ViiV Healthcare\u2019s cabotegravir for HIV prevention receives positive CHMP opinion from European Medicines Agency 2023 [Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/viiv-healthcare-s-cabotegravir-for-hiv-prevention-receives-positive-chmp-opinion-from-european-medicines-agency\/"},{"key":"30474_CR5","unstructured":"Scottish Medicines Consortium. Cabotegravir (Apretude\u00ae) is accepted for restricted use within NHS Scotland. [ (2025). Available from: https:\/\/scottishmedicines.org.uk\/medicines-advice\/cabotegravir-apretude-full-smc2718\/#:~:text=following%20a%20full%20submission%3A,for%20restricted%20use%20within%20NHSScotland"},{"key":"30474_CR6","doi-asserted-by":"crossref","unstructured":"Stansfield, S. et al. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in 3 high resource settings: A model comparison analysis. J. Int. AIDS. Soc. (2023).","DOI":"10.1002\/jia2.26109"},{"key":"30474_CR7","doi-asserted-by":"crossref","unstructured":"Wang, H., Jonas, K. & Van de Vijver, D. Epidemiological Impact of Targeting Long-Acting Injectable Cabotegravir To MSM with Low PrEP Use Adherence in the Netherlands (A Mathematical Modelling Study, 2023).","DOI":"10.2139\/ssrn.4415665"},{"key":"30474_CR8","doi-asserted-by":"crossref","unstructured":"Wang, H., Zimmermann, H. M. L., van de Vijver, D. & Jonas, K. J. Intention and preference to use long-acting injectable PrEP among MSM in the netherlands: a diffusion of innovation approach. AIDS Care :1\u201312. (2024).","DOI":"10.1080\/09540121.2024.2307378"},{"key":"30474_CR9","first-page":"1","volume":"28","author":"A Raccagni","year":"2023","unstructured":"Raccagni, A. et al. High propensity to switch to Long-acting injectable HIV PrEP with cabotegravir in a cohort of oral PrEP experienced men who have sex with men in Italy. AIDS Behav. 28, 1\u20135 (2023).","journal-title":"AIDS Behav."},{"issue":"8","key":"30474_CR10","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1007\/s10461-021-03200-4","volume":"25","author":"M van Dijk","year":"2021","unstructured":"van Dijk, M., de Wit, J. B. F., Guadamuz, T. E., Martinez, J. E. & Jonas, K. J. Slow uptake of prep: behavioral predictors and the influence of price on PrEP uptake among MSM with a high interest in PrEP. AIDS Behav. 25 (8), 2382\u20132390 (2021).","journal-title":"AIDS Behav."},{"issue":"16","key":"30474_CR11","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1097\/QAD.0000000000001627","volume":"31","author":"E Hoornenborg","year":"2017","unstructured":"Hoornenborg, E., Krakower, D. S., Prins, M. & Mayer, K. H. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. AIDS (London England). 31 (16), 2179\u20132191 (2017).","journal-title":"AIDS (London England)"},{"issue":"6","key":"30474_CR12","doi-asserted-by":"publisher","first-page":"e26516","DOI":"10.1002\/jia2.26516","volume":"28","author":"H Wang","year":"2025","unstructured":"Wang, H., Popping, S., van de Vijver, D. & Jonas, K. J. Epidemiological impact and cost-effectiveness analysis of PrEP provision expansion among MSM in the Netherlands. J. Int. AIDS. Soc. 28 (6), e26516 (2025).","journal-title":"J. Int. AIDS. Soc."},{"issue":"5","key":"30474_CR13","doi-asserted-by":"publisher","first-page":"e26089","DOI":"10.1002\/jia2.26089","volume":"26","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Spatio-temporal changes in pre-exposure prophylaxis uptake among MSM in Mainland France between 2016 and 2021: a bayesian small area approach with MSM population Estimation. J. Int. AIDS. Soc. 26 (5), e26089 (2023).","journal-title":"J. Int. AIDS. Soc."},{"key":"30474_CR14","doi-asserted-by":"publisher","first-page":"100486","DOI":"10.1016\/j.lanepe.2022.100486","volume":"22","author":"S Billioti de Gage","year":"2022","unstructured":"Billioti de Gage, S., Desplas, D. & Dray-Spira, R. Roll-out of HIV pre-exposure prophylaxis use in france: A nationwide observational study from 2016 to 2021. Lancet Reg. Health - Europe. 22, 100486 (2022).","journal-title":"Lancet Reg. Health - Europe"},{"issue":"Suppl 1","key":"30474_CR15","first-page":"A80","volume":"100","author":"S Venturelli","year":"2024","unstructured":"Venturelli, S. et al. SC-13\u2005Impact of PrEP cost on prophylaxis initiation in an Italian centre. Sex. Transm. Infect. 100 (Suppl 1), A80 (2024).","journal-title":"Sex. Transm. Infect."},{"key":"30474_CR16","doi-asserted-by":"crossref","unstructured":"Wang, H. et al. Determinants of PrEP Uptake, intention and awareness in the netherlands: A Socio-Spatial analysis. Int. J. Environ. Res. Public Health ;19(14). (2022).","DOI":"10.3390\/ijerph19148829"},{"issue":"4","key":"30474_CR17","doi-asserted-by":"publisher","first-page":"e083837","DOI":"10.1136\/bmjopen-2023-083837","volume":"14","author":"SW Cole","year":"2024","unstructured":"Cole, S. W. et al. Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment. BMJ Open. 14 (4), e083837 (2024).","journal-title":"BMJ Open."},{"key":"30474_CR18","doi-asserted-by":"publisher","first-page":"1367830","DOI":"10.3389\/fphar.2024.1367830","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Willingness to pay and price elasticity of demand for long-acting injectable cabotegravir among men who have sex with men in Guangxi, China. Front. Pharmacol. 15, 1367830 (2024).","journal-title":"Front. Pharmacol."},{"key":"30474_CR19","unstructured":"Traeger, M. et al. Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System 2025 [Available from: https:\/\/www.croiconference.org\/abstract\/3308-2025\/"},{"issue":"8","key":"30474_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10198-013-0526-8","volume":"15","author":"A Kiil","year":"2014","unstructured":"Kiil, A. & Houlberg, K. How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011. Eur. J. Health Econ. 15 (8), 813\u2013828 (2014).","journal-title":"Eur. J. Health Econ."},{"issue":"7","key":"30474_CR21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s10461-012-0240-z","volume":"16","author":"A Pettifor","year":"2012","unstructured":"Pettifor, A., MacPhail, C., Nguyen, N. & Rosenberg, M. Can money prevent the spread of HIV? A review of cash payments for HIV prevention. AIDS Behav. 16 (7), 1729\u20131738 (2012).","journal-title":"AIDS Behav."},{"issue":"7","key":"30474_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40273-022-01231-w","volume":"41","author":"S Torres-Rueda","year":"2023","unstructured":"Torres-Rueda, S. et al. Health economics research on Non-surgical biomedical HIV prevention: Identifying gaps and proposing a way forward. PharmacoEconomics 41 (7), 787\u2013802 (2023).","journal-title":"PharmacoEconomics"},{"key":"30474_CR23","doi-asserted-by":"crossref","unstructured":"Kolstee, J. et al. Design and Methods of the - Understanding pre-exposure prophylaxis modalities for HIV prevention in European communities - (PROTECT) Survey. medRxiv. 2024:2024.11.04.24316697.","DOI":"10.1101\/2024.11.04.24316697"},{"issue":"48","key":"30474_CR24","doi-asserted-by":"publisher","first-page":"2400347","DOI":"10.2807\/1560-7917.ES.2024.29.48.2400347","volume":"29","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Likelihood of HIV and recent bacterial sexually transmitted infections among transgender and non-binary individuals in 20 European countries, October 2023 to April 2024. Eurosurveillance 29 (48), 2400347 (2024).","journal-title":"Eurosurveillance"},{"issue":"9","key":"30474_CR25","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jbusres.2012.02.029","volume":"66","author":"S Dolnicar","year":"2013","unstructured":"Dolnicar, S. & Gr\u00fcn, B. Translating between survey answer formats. J. Bus. Res. 66 (9), 1298\u20131306 (2013).","journal-title":"J. Bus. Res."},{"issue":"1","key":"30474_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s43058-020-00050-4","volume":"1","author":"J Fishman","year":"2020","unstructured":"Fishman, J., Lushin, V. & Mandell, D. S. Predicting implementation: Comparing validated measures of intention and assessing the role of motivation when designing behavioral interventions. Implement. Sci. Commun. 1 (1), 81 (2020).","journal-title":"Implement. Sci. Commun."},{"issue":"1","key":"30474_CR27","doi-asserted-by":"publisher","first-page":"22252","DOI":"10.1038\/s41598-021-01634-3","volume":"11","author":"DHS Tan","year":"2021","unstructured":"Tan, D. H. S. et al. Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment. Sci. Rep. 11 (1), 22252 (2021).","journal-title":"Sci. Rep."},{"issue":"12","key":"30474_CR28","doi-asserted-by":"publisher","first-page":"e835","DOI":"10.1016\/S2352-3018(20)30197-1","volume":"7","author":"WPH van Bilsen","year":"2020","unstructured":"van Bilsen, W. P. H., Zimmermann, H. M. L., Boyd, A. & Davidovich, U. Burden of living with HIV among men who have sex with men: A mixed-methods study. Lancet HIV. 7 (12), e835\u2013e43 (2020).","journal-title":"Lancet HIV"},{"key":"30474_CR29","doi-asserted-by":"crossref","unstructured":"Wang, H. et al. Interest in and preference for long-acting injectable PrEP among men who have sex with men, trans* individuals, and cis-gender heterosexual women: a global systematic review and meta-analysis. J. Acquir. Immune Defic. Syndr. (2025).","DOI":"10.1101\/2024.09.25.24314401"},{"key":"30474_CR30","unstructured":"Patel, R. Why Is Cabotegravir Rollout So Slow? 2024 [Available from: https:\/\/www.croiconference.org\/abstract\/why-is-cabotegravir-rollout-so-slow\/"},{"key":"30474_CR31","doi-asserted-by":"crossref","unstructured":"Wang, H. et al. Oral PrEP use and intention to use long-acting PrEP regimens among MSM accessing PrEP via governmental and non-governmental provision pathways, 20 European countries, October 2023 to April 2024. Euro. Surveill ;30(34). (2025).","DOI":"10.2807\/1560-7917.ES.2025.30.34.2500122"},{"issue":"2","key":"30474_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/COH.0000000000000034","volume":"9","author":"F Tanser","year":"2014","unstructured":"Tanser, F., de Oliveira, T., Maheu-Giroux, M. & B\u00e4rnighausen, T. Concentrated HIV subepidemics in generalized epidemic settings. Curr. Opin. HIV AIDS. 9 (2), 115\u2013125 (2014).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"30474_CR33","unstructured":"UNAIDS. End Inequalities, End, A. I. D. S. & Global, A. I. D. S. Strategy 2021\u20132026 2021 [Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2021\/2021-2026-global-AIDS-strategy"},{"issue":"10337","key":"30474_CR34","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe, S. et al. Cabotegravir for the prevention of HIV-1 in women: Results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399 (10337), 1779\u20131789 (2022).","journal-title":"Lancet"},{"issue":"4","key":"30474_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/COH.0000000000000733","volume":"17","author":"MA Spinelli","year":"2022","unstructured":"Spinelli, M. A., Grinsztejn, B. & Landovitz, R. J. Promises and challenges: Cabotegravir for preexposure prophylaxis. Curr. Opin. HIV AIDS. 17 (4), 186\u2013191 (2022).","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"30474_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0000000000003635","volume":"99","author":"H Wang","year":"2025","unstructured":"Wang, H., Delnoij, M., Zimmermann, H. M. L. & Jonas, K. J. The disparities of PrEP adherence among men who have sex with men between the global South and the global north: An updated determinantal global Meta-Analysis. JAIDS J. Acquir. Immune Defic. Syndr. 99 (1), 1\u20138 (2025).","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"30474_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1186\/s12889-023-15540-y","volume":"23","author":"E Van Landeghem","year":"2023","unstructured":"Van Landeghem, E. et al. Insights into barriers and facilitators in PrEP uptake and use among migrant men and transwomen who have sex with men in Belgium. BMC Public. Health. 23 (1), 712 (2023).","journal-title":"BMC Public. Health"},{"issue":"8","key":"30474_CR38","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1016\/S2468-2667(23)00105-6","volume":"8","author":"W Tieosapjaroen","year":"2023","unstructured":"Tieosapjaroen, W. et al. Improving access to oral pre-exposure prophylaxis for HIV among international migrant populations. Lancet Public. Health. 8 (8), e651\u2013e8 (2023).","journal-title":"Lancet Public. Health"},{"key":"30474_CR39","unstructured":"ViiV Healthcare. ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative HIV prevention measure 2023 [Available from: https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2022\/may\/viiv-healthcare-commits-to-grant-voluntary-licence-for-patents\/"},{"issue":"11","key":"30474_CR40","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","volume":"29","author":"JE Haberer","year":"2015","unstructured":"Haberer, J. E. et al. Defining success with HIV pre-exposure prophylaxis: A prevention-effective adherence paradigm. Aids 29 (11), 1277\u20131285 (2015).","journal-title":"Aids"},{"issue":"1","key":"30474_CR41","doi-asserted-by":"publisher","first-page":"e25872","DOI":"10.1002\/jia2.25872","volume":"25","author":"L-G Bekker","year":"2022","unstructured":"Bekker, L-G., Pike, C. & Hillier, S. L. HIV prevention: better choice for better coverage. J. Int. AIDS. Soc. 25 (1), e25872 (2022).","journal-title":"J. Int. AIDS. Soc."},{"issue":"48","key":"30474_CR42","doi-asserted-by":"publisher","first-page":"2400778","DOI":"10.2807\/1560-7917.ES.2024.29.48.2400778","volume":"29","author":"V Bremer","year":"2024","unstructured":"Bremer, V. & Pharris, A. Five years to 2030: reaching underserved populations is key to ending the AIDS epidemic in Europe. Eurosurveillance 29 (48), 2400778 (2024).","journal-title":"Eurosurveillance"},{"key":"30474_CR43","doi-asserted-by":"publisher","first-page":"e72491","DOI":"10.2196\/72491","volume":"11","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. Perceptions of Long-Acting injectable pre-exposure prophylaxis among men who have sex with men and transgender individuals in Europe using structural text modeling technique: Cross-Sectional study. JMIR Public. Health Surveill. 11, e72491 (2025).","journal-title":"JMIR Public. Health Surveill"},{"key":"30474_CR44","doi-asserted-by":"publisher","first-page":"109741","DOI":"10.1016\/j.drugalcdep.2022.109741","volume":"243","author":"H Wang","year":"2023","unstructured":"Wang, H., Jonas, K. J. & Guadamuz, T. E. Chemsex and chemsex associated substance use among men who have sex with men in asia: A systematic review and meta-analysis. Drug Alcohol Depend. 243, 109741 (2023).","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"30474_CR45","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1007\/s10461-022-03730-5","volume":"26","author":"L De La Mora","year":"2022","unstructured":"De La Mora, L. et al. Chemsex practices in prep: Beyond addiction and risk toward a healthy sex Life\u2014Baseline experiences from a Hospital-Based PrEP program in Barcelona, Spain. AIDS Behav. 26 (12), 4055\u20134062 (2022).","journal-title":"AIDS Behav."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30474-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:25:57Z","timestamp":1767882357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30474-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30474"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30474-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the PROTECT study was granted by the Ethics Review Committee Psychology and Neuroscience of Maastricht University (OZL_262_08_01_2023_S21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"HW, JK, HMLZ, and KJJ report there are no direct competing interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"968"}}